TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20199827

Group type: EXPERIMENTAL
Intervention: LC n‐3 PUFA‐rich meal
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 25
Study: 17875241

Group type: EXPERIMENTAL
Intervention: Alprostadil 5‐20 microg powder for injection
Number of subjects: 187

Group type: COMPARATOR
Intervention: Vasoactive intestinal polypeptide (VIP) and phentolamine
Number of subjects: 187

Group type: COMPARATOR
Intervention: VIP/phentolamine (ampoule)
Number of subjects: 187

Group type: COMPARATOR
Intervention: VIP/phentolamine (auto-injector)
Number of subjects: 187
Study: 16076378

Group type: EXPERIMENTAL
Intervention: 3 g sevelamer hydrochloride + 3 g calcium bicarbonate (CaCO3)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 3 g calcium bicarbonate (CaCO3) alone
Number of subjects: 46
Study: 12132060

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% plus sufentanil 0.5 microg/mL
Number of subjects: 30
Study: 10573104

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 30 mg/day orally for 2 years
Number of subjects: 594

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 30 mg/day orally for 2 years + UFT 300 mg/day orally for 2 years
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: UFT 300 mg/day orally for 2 years
Number of subjects: 594

Group type: COMPARATOR
Intervention: UFT 300 mg/day orally for 2 years + Tamoxifen (TAM) 30 mg/day
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Combined treatment of MMC, TAM, and UFT
Number of subjects: 594
Study: 8692031

Group type: EXPERIMENTAL
Intervention: CHO trial (150-g x L(‐1) CHO solution)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHO + MCT trial (70 energy% CHO-30 en% MCT suspension containing 29 g MCT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HCHO + MCT trial (150-g x L(‐1) CHO solution plus 20 g MCT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control trial (13C-background control trial)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MCT ingestion
Number of subjects: 9
Study: 1858990

Group type: EXPERIMENTAL
Intervention: 0.5 mg of atropine and 50 mg of meperidine plus oral placebo (n = 14)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 10 mg of oral diazepam and intramuscular placebo (2 mL NaCl, concentration = 0.9) (n = 14)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oral and intramuscular placebo (n = 14)
Number of subjects: 42
Study: 6356965

Group type: EXPERIMENTAL
Intervention: Budesonide (topically administered glucocorticoid) for 1 week
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31923303

Group type: EXPERIMENTAL
Intervention: Implantoplasty
Number of subjects: 31

Group type: COMPARATOR
Intervention: Glycine air polishing
Number of subjects: 31
Study: 30914500

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (1.5 g DHA + 0.3 g EPA/day)
Number of subjects: 43
Study: 29608336

Group type: EXPERIMENTAL
Intervention: Virtual task using the Kinect system
Number of subjects: 22

Group type: COMPARATOR
Intervention: Real task (touching a real object)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Virtual task
Number of subjects: 22

Group type: COMPARATOR
Intervention: Real task
Number of subjects: 22
Study: 26941086

Group type: EXPERIMENTAL
Intervention: Rectal indomethacin alone
Number of subjects: 1430

Group type: COMPARATOR
Intervention: Combination of rectal indomethacin and prophylactic pancreatic stent placement (PSP)
Number of subjects: 1430
Study: 24571395

Group type: EXPERIMENTAL
Intervention: salbutamol MDI with CPT
Number of subjects: 48

Group type: COMPARATOR
Intervention: salbutamol MDI without CPT
Number of subjects: 48
Study: 21327799

Group type: EXPERIMENTAL
Intervention: seT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: iCEM
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clearfil SA
Number of subjects: 32
Study: 19083105

Group type: EXPERIMENTAL
Intervention: Total fat
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Saturated fat
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Available carbohydrates
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 366
Study: 17805077

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 15506067

Group type: EXPERIMENTAL
Intervention: rilmenidine 1 mg bid
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 10865218

Group type: EXPERIMENTAL
Intervention: 20 mg once a week (weekly alendronate group)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 10 mg daily (orally) for 1 month out of 3 (cyclical alendronate group)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Calcium/vitamin D supplements (control group)
Number of subjects: 124
Study: 9124166

Group type: EXPERIMENTAL
Intervention: Sotalol 80 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotalol 160 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8228077

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.i.d.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: H2-antagonist (single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: H2-antagonist (14-day chronic dosing)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: H2-antagonist (28-day chronic dosing)
Number of subjects: 10
Study: 3536469

Group type: EXPERIMENTAL
Intervention: Vigabatrin (1.0 g twice daily for patients ≤ 65 kg; 1.5 g twice daily for patients > 65 kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3042009

Group type: EXPERIMENTAL
Intervention: Dithranol + UVB therapy (27 patients)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Dithranol only (21 patients)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Dithranol only (16 patients who cleared)
Number of subjects: 53
Study: 30667588

Group type: EXPERIMENTAL
Intervention: Weight Management Intervention (WMI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (Cardiac Rehabilitation alone)
Number of subjects: 43
Study: 28302275

Group type: EXPERIMENTAL
Intervention: 3D vision laparoscopic simulator training
Number of subjects: 34

Group type: COMPARATOR
Intervention: 2D vision laparoscopic simulator training
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Retention test under 2D conditions after 3D training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Retention test under 2D conditions after 2D training
Number of subjects: 34
Study: 26471852

Group type: EXPERIMENTAL
Intervention: Stretching and strengthening exercises plus manual therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Stretching and strengthening exercises alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (exercise alone and exercise plus manual therapy)
Number of subjects: 46
Study: 23834545

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg kg(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 21660778

Group type: EXPERIMENTAL
Intervention: 10 paced chapters
Number of subjects: 28

Group type: COMPARATOR
Intervention: One book with 10 chapters
Number of subjects: 28
Study: 18669012

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWHs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirically adjusted doses of LMWH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 16679545

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/d sodium selenite in addition to chemotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 30
Study: 12780888

Group type: EXPERIMENTAL
Intervention: Topical diltiazem (2%) ointment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Glyceryltrinitrate (GTN) (0.5%) ointment
Number of subjects: 43
Study: 10840128

Group type: EXPERIMENTAL
Intervention: Passive oddball task with labial /ba/‐dental /da/ contrasts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive oddball task with Hindi dental /da/‐retroflex /da/ contrasts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive oddball task with within‐category (two /ba/ tokens) contrasts
Number of subjects: 0
Study: 9221182

Group type: EXPERIMENTAL
Intervention: Consupren at an initial dose of 5 mg/kg/d (CS group, n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cyclophosphamide at a dose of 1.5 mg/kg/d (K group, n = 11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Consupren (CS group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cyclophosphamide (K group)
Number of subjects: 30
Study: 1587713

Group type: EXPERIMENTAL
Intervention: 4.5 mg all‐rac‐alpha‐tocopherol acetate/kg/d intravenously for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received the same fat emulsions without supplemented vitamin E
Number of subjects: 0
Study: 2933186

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (STK)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: STK and coronary bypass surgery within 24 hr
Number of subjects: 67

Group type: COMPARATOR
Intervention: No successful reperfusion with STK
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: STK treatment within 2 hr of onset
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: STK treatment after 2 hr of onset
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Successfully reperfused patients
Number of subjects: 67

Group type: COMPARATOR
Intervention: Partial reperfusion
Number of subjects: 67

Group type: COMPARATOR
Intervention: Failed reperfusion
Number of subjects: 67
Study: 30133507

Group type: EXPERIMENTAL
Intervention: Adipose tissue content of total 18:1t (quintiles 5 versus 1)
Number of subjects: 3156

Group type: EXPERIMENTAL
Intervention: Adipose tissue content of 18:1 Δ6‐10t (quintiles 5 versus 1)
Number of subjects: 3156

Group type: EXPERIMENTAL
Intervention: Adipose tissue content of 18:1 Δ11t (quintiles 5 versus 1)
Number of subjects: 3156

Group type: EXPERIMENTAL
Intervention: Adipose tissue content of 18:2 Δ9c, 11t
Number of subjects: 3156
Study: 27161257

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg, three times daily)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 24878421

Group type: EXPERIMENTAL
Intervention: Capsaicin cough challenge at days 0 and 1
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Capsaicin cough challenge at days 2 and 3
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Capsaicin cough challenge at days 4 and 5
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Healthy baseline measurement (recovery) 4-8 weeks post-viral infection
Number of subjects: 42
Study: 23107220

Group type: EXPERIMENTAL
Intervention: Intranasal insulin 40 IU q.i.d. (n = 34)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 62
Study: 20654060

Group type: EXPERIMENTAL
Intervention: Akreos AO aberration-free aspheric IOL
Number of subjects: 130

Group type: COMPARATOR
Intervention: Spherical IOL (KS-1, Cannon Staar)
Number of subjects: 130
Study: 17445333

Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m2 weekly
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vinorelbine 6 mg/m2 weekly
Number of subjects: 72
Study: 15729485

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium (IPM/CS) plus betamethasone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no IPM/CS or betamethasone)
Number of subjects: 100
Study: 12729866

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication (drug trial)
Number of subjects: 714

Group type: COMPARATOR
Intervention: Epidemiological study (control)
Number of subjects: 714
Study: 10629368

Group type: EXPERIMENTAL
Intervention: Induction of labor using oral prostaglandin E(2) at 37 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 36
Study: 9183091

Group type: EXPERIMENTAL
Intervention: Intervention group received a sheet illustrating eight positive aspects of breast feeding and a questionnaire on breast feeding at 36 weeks antenatal visit.
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group received routine antenatal care.
Number of subjects: 193
Study: 7902966

Group type: EXPERIMENTAL
Intervention: Combination of 2 out of 3 partial autonomic blockers (indoramin, propranolol, atropine)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3710284

Group type: EXPERIMENTAL
Intervention: Oral zinc aspartate application during pregnancy
Number of subjects: 524

Group type: COMPARATOR
Intervention: Control group (no zinc application)
Number of subjects: 524
Study: 31296044

Group type: EXPERIMENTAL
Intervention: Endoscopic release (ER)
Number of subjects: 60

Group type: COMPARATOR
Intervention: In situ open neurolysis (OR)
Number of subjects: 60
Study: 30483715

Group type: EXPERIMENTAL
Intervention: Diode laser treatment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional root canal preparation and calcium hydroxide sealant (Control)
Number of subjects: 78
Study: 28730888

Group type: EXPERIMENTAL
Intervention: Prehabilitation group (moderate endurance and resistance training plus breathing exercises, 3-5 times per week)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prehabilitation group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 26065986

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 16490

Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate 110 mg
Number of subjects: 16490

Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate 150 mg
Number of subjects: 16490
Study: 24035168

Group type: EXPERIMENTAL
Intervention: niacin-ER (extended-release niacin) at a maximum of 1,500 mg/day for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: niacin-ER
Number of subjects: 27

Group type: COMPARATOR
Intervention: niacin-ER and placebo
Number of subjects: 27
Study: 21764404

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention program
Number of subjects: 71

Group type: COMPARATOR
Intervention: Credible control program
Number of subjects: 71
Study: 18783622

Group type: EXPERIMENTAL
Intervention: RTEC with nutrition education
Number of subjects: 147

Group type: COMPARATOR
Intervention: RTEC alone (1 or 2 doses)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 147
Study: 16644439

Group type: EXPERIMENTAL
Intervention: Myocardial Contrast Echocardiography (MCE)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single Photon Emission Computed Tomography (SPECT)
Number of subjects: 72
Study: 12553385

Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (CSA) with prilocaine 2% 40 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous epidural anaesthesia (CEA) with prilocaine 1% 150 mg
Number of subjects: 30
Study: 10376170

Group type: EXPERIMENTAL
Intervention: Migraine in patients
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Active migraine in patients
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Decreased migraine in patients
Number of subjects: 460

Group type: COMPARATOR
Intervention: Ceased migraine in controls
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Ocular pain in patients with migraine
Number of subjects: 460
Study: 8694727

Group type: EXPERIMENTAL
Intervention: 1.0% rimexolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1% fluorometholone
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1% dexamethasone sodium phosphate
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.0% prednisolone acetate
Number of subjects: 40
Study: 1910799

Group type: EXPERIMENTAL
Intervention: Droperidol 75 microgram/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Droperidol 20 microgram/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study: 7049341

Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Safflower oil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patients with Friedreich's Ataxia
Number of subjects: 22
Study: 31393676

Group type: EXPERIMENTAL
Intervention: 3D vision
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2D vision
Number of subjects: 60
Study: 31537777

Group type: EXPERIMENTAL
Intervention: Early rehabilitation therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (persistent monitoring)
Number of subjects: 42
Study: 28705206

Group type: EXPERIMENTAL
Intervention: Hyrax-type expander anchored to permanent teeth
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Modified Hyrax-type expander anchored to deciduous teeth
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Modified Haas-type expander anchored to deciduous teeth
Number of subjects: 44
Study: 26509683

Group type: EXPERIMENTAL
Intervention: Active LITUS (n = 20) at a frequency of 3 MHz and an energy intensity of 0.132 W/cm² continuously for 3 hours using 1 transducer
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Active LITUS (n = 20) at a frequency of 3 MHz and an energy intensity of 0.132 W/cm² continuously for 3 hours using 2 transducers
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Active LITUS (n = 20)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo LITUS (n = 6)
Number of subjects: 26
Study: 23838771

Group type: COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PALs)
Number of subjects: 84
Study: 22559158

Group type: EXPERIMENTAL
Intervention: S-1 and cisplatin (SP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: gemcitabine and cisplatin (GP)
Number of subjects: 96
Study: 19177536

Group type: EXPERIMENTAL
Intervention: Land-based exercise program
Number of subjects: 102

Group type: COMPARATOR
Intervention: Water-based exercise program
Number of subjects: 102
Study: 18057477

Group type: EXPERIMENTAL
Intervention: Phytomenadione (vitamin K1), 1 mg intramuscularly
Number of subjects: 170

Group type: COMPARATOR
Intervention: Menadione (vitamin K3), 1 mg intramuscularly
Number of subjects: 170
Study: 11239326

Group type: EXPERIMENTAL
Intervention: Generic contoured cushion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Flat foam cushion
Number of subjects: 9
Study: 9602575

Group type: EXPERIMENTAL
Intervention: i.v. morphine, i.m. diclofenac and intercostal nerve blocks from T2 to T11, 20 min before operation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo injections before operation, and i.v. morphine, i.m. diclofenac and intercostal nerve blocks from T2 to T11 at the end of surgery
Number of subjects: 30
Study: 7767541

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, four times daily for 16 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms, four times daily for 16 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2123142

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with 15 or 30 kcal/kg.day and 0.30 g of N with standard or branch-chain (BC) enriched AA solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with 30 kcal/kg.day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCAA-enriched AA solutions
Number of subjects: 0
Study: 508132

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study: 31855097

Group type: EXPERIMENTAL
Intervention: Online community support and information sharing regarding stress urinary incontinence management.
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Discussion of risk factors, prevention strategies, and treatment recommendations.
Number of subjects: 762
Study: 30936584

Group type: EXPERIMENTAL
Intervention: Flow Awareness Technology (Group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Level Detector (Group B)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 33
Study: 28549081

Group type: EXPERIMENTAL
Intervention: King Vision videolaryngoscope (KVL)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Miller direct laryngoscope (DL)
Number of subjects: 200
Study: 25854809

Group type: EXPERIMENTAL
Intervention: Home-based occupational therapy for 10 weeks
Number of subjects: 191

Group type: COMPARATOR
Intervention: Usual care (no occupational therapy)
Number of subjects: 191
Study: 25476074

Group type: EXPERIMENTAL
Intervention: Furosemide therapy, anisodamine, nitroglycerin, beta blocker or cedilanid
Number of subjects: 120
Study: 22030597

Group type: EXPERIMENTAL
Intervention: Triple-combination treatment (olmesartan medoxomil 40/amlodipine besylate 10/hydrochlorothiazide 25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple-combination treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual-combination treatments
Number of subjects: 0
Study: 19387957

Group type: EXPERIMENTAL
Intervention: Catheter ablation of AF
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (younger patients)
Number of subjects: 15
Study: 17560141

Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 14984936

Group type: EXPERIMENTAL
Intervention: Whole pelvic radiation therapy (RT)
Number of subjects: 392

Group type: COMPARATOR
Intervention: No additional therapy (NAT)
Number of subjects: 392
Study: 12219873

Group type: EXPERIMENTAL
Intervention: Braun PrecisionSensor 2000 with position sensor
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Braun PrecisionSensor 2000 without position sensor
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ambulatory 24-hour blood pressure measurement (ABPM)
Number of subjects: 43
Study: 10402973

Group type: EXPERIMENTAL
Intervention: SPf66 vaccine (three doses at 1, 2, and 7 months of age)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 1207
Study: 8697925

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57